Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 201...
02 Août 2018 - 2:30PM
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that
it will host a webcast and conference call to discuss the Company’s
financial results for the quarter ended June 30, 2018, and provide
a general business overview on Thursday, August 9, 2018,
at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call DetailsThe live
conference call on Thursday, August 9, 2018, at 8:30 a.m.
ET, can be accessed by phone by calling (844) 452-6828
from the United States and Canada or 1 (765)
507-2588 internationally and using the passcode 6650817. The
webcast can be accessed live on the Investor Relations section of
the Company's website at http://investors.portola.com. It will
be archived for 30 days following the call.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor for the prevention of VTE in adult patients
hospitalized for an acute medical illness, and
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], the first and only antidote for the Factor Xa
inhibitors rivaroxaban and apixaban. The company also is advancing
cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic
cancers.
Investor Contact:Cara MillerPortola
Pharmaceuticalsir@portola.com |
|
Media Contact:Laurie MasonsonPure
Communicationslmasonson@purecommunications.com |
|
|
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur